Mar 11, 2026 | Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi

Vertex clears Phase 3 in kidney disease as after-hoursshares surge. Plus Lilly commits $3B to China GLP-1 manufacturing, UCB's Bimzelx defeats AbbVie's Skyrizi head-to-head, and an FDA approval for fewer than 50 patients worldwide. Wednesday's essential pharma intelligence.#pharma, pharmaceutical, #FDA, #clinical trials, #biotech, drug approvals, #healthcare, #pharma podcast, #The Pharma #Closeout, #Vertex, #kidney disease, #Eli Lilly, #China manufacturing, #GLP-1, #UCB, #Bimzelx, #AbbVie, #Skyrizi,#psoriatic arthritis, #GSK, #leucovorin, #cerebral folate deficiency, #Bristol Myers, #mezigdomide, #multiple myeloma, #Xenon, #epilepsy, #BioNTech, #mRNA, #Roche,#giredestrant, #Lilly